| |
 |
|
|
|
|
|
Poster: 186
Visits: 19
Title: Targeting Mutated BRAF with Vemurafenib is Safe and Highly Active in Relapsed/Refractory Hairy Cell Leukemia: a Phase-2 Italian Clinical Trial (HCL-PG01)
Authors: Enrico Tiacci ,
Centre: Institute of Hematology
|
|
You must be registered to reply or comment.
|
|
TARGETING MUTATED BRAF WITH VEMURAFENIB IS SAFE AND HIGHLY ACTIVE IN RELAPSED/REFRACTORY HAIRY CELL LEUKEMIA: A PHASE-2 ITALIAN CLINICAL TRIAL (HCL-PG01)
|
|
| You must be registered to reply or comment. |
|
|
|
|
|
|
| Most viewed poster for this congress |
|
|
Poster: 9
Visits: 649
Title: Ibrutinib in combination with Rituximab for Relapsed Mantle Cell Lymphoma: An Update from a Phase II Clinical Trial
Authors: Michael Wang ,
Centre: The University of Texas MD Anderson Cancer Center
|
|
|
|
|
|
|
| Poster most viewed in this topic |
|
|
Poster: 192
Visits: 298
Title: Extended Dosing Lenalidomide with Intensified Rituximab in Untreated Indolent NHL
Authors: Nathan Fowler , Chan Yoon Cheah, Sattva Neelapu, Loretta Nastoupil, Francesco Turturro, Fredrick Hagemeister, Larry W. Kwak, Jorge Romaguera, Michelle Fanale, Luis Fayad, Linda Claret, Lei Feng, R Eric Davis, and Felipe Samaniego
Centre: MD Anderson Cancer Center
|
|
|
|
